Company profile for Incendia Therapeutics

Incendia Therapeutics

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

pharmacompass-1-m-2025-12-22

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

Contact Supplier

pharmacompass-2-m-2025-11-03

Contact Supplier

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

8 News #PharmaBuzz

media
8 News #PharmaBuzz

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Icendia understands that cancer cells generate a hostile microenvironment that prioritizes their survival while harming host tissues. To combat this, Incendia focuses on targeting the structural and biochemical foundations of the tumor microenvironment. This strategy aims to facilitate the access of host immune cells and immuno-oncology therapies, enhancing their ability to effectively target and destroy cancer cells. Through ...

Icendia understands that cancer cells generate a hostile microenvironment that prioritizes their survival while harming host tissues. To combat this, Incendia focuses on targeting the structural and biochemical foundations of the tumor microenvironment. This strategy aims to facilitate the access of host immune cells and immuno-oncology therapies, enhancing their ability to effectively target and destroy cancer cells. Through this innovative approach, we strive to improve treatment outcomes and empower the body’s immune system in the fight against cancer.

DCAT WeekDCAT Week

Not Confirmed

Not Confirmed

23-26 March, 2026

New York, U.S.A
BIO Partnering at JPMBIO Partnering at JPM

Not Confirmed

Not Confirmed

12-15 January, 2026

San Francisco Marriott Marquis, California
Biotech ShowcaseBiotech Showcase

Not Confirmed

Not Confirmed

12-14 January, 2026

San Diego, California, U.S.A

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

United_States_of_America Flag

Country

Country

U.S.A

Address

Address

One Canal Park Suite# 200 Cambridge, MA 02141

Telephone

Telephone

Email

enquiries@pharmacompass.com

Client Website

Website

https://www.incendiatx.com/

Linkedin

youtube

YouTube

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Incendia Therapeutics Showcases PRTH-101 In Thymic Cancers

02 Oct 2025

// GLOBENEWSWIRE

Incendia Therapeutics Adds Louis G. Lange, M.D., Ph.D., To Board

11 Dec 2024

// BUSINESSWIRE

Incendia Therapeutics Appoints Bradford Smith as CFO

03 Dec 2024

// BUSINESSWIRE

DELFI Diagnostics Partners with Incendia on Phase 1 Trial

28 Oct 2024

// PR NEWSWIRE

XtalPi and Parthenon Enter Into AI-Powered Antibody Discovery Partnership

05 Sep 2023

// PR NEWSWIRE

Parthenon Announces Publication in Journal for ImmunoTherapy of Cancer PRTH-101

22 Jun 2023

// BUSINESSWIRE

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Market Place

Home

Menu

Post Enquiry

Market Place

Search